An important question, and one that deserves a detailed answer, if I may, Llywydd. I can say that health boards in Wales are able to offer multiparametric scans, in line with the current guidance from the National Institute for Health and Care Excellence. That guidance currently recommends the mpMRI for people with a negative biopsy, to determine whether another biopsy is needed, and whether the management of a proven cancer will benefit from staging of the tumour. The what's called 'PROMIS trial' indicated that people with suspected prostate cancer might benefit from having their mpMRI prior to biopsy. NICE is reviewing its guidance and is expected to issue recommendations in the early part of next year. In the meantime, evidence is being considered by the Wales urology board. It's fair to say there are different views among the clinicians about the implications of recent evidence, with some health boards implementing elements of a revised approach. What I can say is that, if NICE recommends pre-biopsy mpMRI for suspected prostate cancer, then we would expect all health boards to amend their care pathways accordingly. In the meantime, health boards will continue to consider the evidence and pathway reforms through the Wales urology board.